DocGo Inc (DCGO)vsEli Lilly and Company (LLY)
DCGO
DocGo Inc
$0.71
-0.20%
HEALTHCARE · Cap: $70.92M
LLY
Eli Lilly and Company
$851.21
+9.80%
HEALTHCARE · Cap: $760.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 20130% more annual revenue ($65.18B vs $322.20M). LLY leads profitability with a 31.7% profit margin vs -56.6%. LLY earns a higher WallStSmart Score of 78/100 (B+).
DCGO
Hold36
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
Grey zone — moderate risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -89.0% — below average capital efficiency
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 28.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : DCGO
The strongest argument for DCGO centers on Price/Book, Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : DCGO
The primary concerns for DCGO are Altman Z-Score, Market Cap, Piotroski F-Score.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
DCGO profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
DCGO carries more volatility with a beta of 0.98 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 36/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DocGo Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
DocGo Inc. is a forward-thinking mobile healthcare service provider that transforms patient access through its cutting-edge logistics and telehealth platform. Focusing on urgent care, diagnostic testing, and health screenings, the company not only improves patient experiences but also optimizes healthcare delivery across various settings. With its robust technological advancements and dedication to expanding healthcare access, DocGo stands out as a compelling investment opportunity in the fast-growing healthtech landscape, appealing to institutional investors seeking growth potential.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?